Quarterly ResultMay 5, 2026, 08:11 AM
Spyre Therapeutics Reports Positive SPY001 Phase 2 Data; Q1 Net Loss $69M
AI Summary
Spyre Therapeutics reported its first quarter 2026 financial results and provided corporate and program updates. The company announced positive topline induction data from Part A of the Phase 2 SKYLINE trial for SPY001, demonstrating best-in-class efficacy potential and a consistent safety profile. Additionally, the RA sub-study of the Phase 2 SKYWAY basket trial was over-enrolled, accelerating its topline readout to the third quarter of 2026. The company reported a net loss of $69.0 million for Q1 2026 and strengthened its balance sheet with $463 million gross proceeds from a public offering, resulting in $1.2 billion in pro forma cash with a runway into the second half of 2029.
Key Highlights
- SPY001 Phase 2 Part A data showed statistically significant RHI reduction of 9.2 points (p<0.0001).
- SPY001 achieved clinical remission of 40% and endoscopic improvement of 51%.
- RA sub-study of SKYWAY Phase 2 trial over-enrolled; topline data expected Q3 2026.
- Q1 2026 Net Loss was $69.0 million, compared to $44.8 million in Q1 2025.
- Cash, cash equivalents, and marketable securities were $741.5 million as of March 31, 2026.
- Pro forma cash was $1.2 billion, with expected runway into H2 2029.
- Raised $463 million gross proceeds from an underwritten public offering.
- R&D expenses increased to $60.4 million in Q1 2026 from $41.6 million in Q1 2025.